Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

FDA Accepts Samsung Bioepis’s Bevacizumab Biosimilar (SB8)

Related Content

Lupin and Zentiva Reach Agreement to Commercialize Certolizumab Pegol Biosimilar

Denosumab Updates: Wyost and Jubbonti Launch as First Denosumab Biosimilars in the U.S.

EMA Adopts Positive Opinions for Multiple Biosimilars

Amgen Files BPCIA Complaints Against Biocon, Shanghai Henlius/Organon and Hikma/Gideon Richter Regarding Denosumab Biosimilars

Kashiv BioSciences Reports Positive Topline Results for XOLAIR® Biosimilar Candidate ADL-018

BioNTech Announces Transaction to Acquire CureVac

Teva and Fosun Partner to Develop a Novel Immunotherapy Targeting Melanoma and Other Cancers

FDA Approves Celltrion’s New Pediatric Formulation of STEQEYMA, Expanding Dosing Flexibility

Goodwin Named Venture Capital Firm of the Year, Hatch-Waxman Litigation Firm of the Year and Life Cycle Firm of the Year at the 2024 LMG Life Sciences Americas Awards

Goodwin Named an LMG Life Sciences Life Cycle Firm for the Twelfth Consecutive Year

LMG Recognizes Goodwin Lawyers and Practices for Excellence in Life Sciences

Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.

Goodwin Named an LMG Life Sciences Life Cycle Firm for the Tenth Consecutive Year

Goodwin Adds Life Sciences and Healthcare Litigation Partner William Jackson

China's Patent Linkage System: Can Strategies that Work in the U.S. System Be Applied to China?

Goodwin Named An LMG Life Sciences Life Cycle Firm For The Ninth Consecutive Year

Life Sciences

Hatch-Waxman, Biologics and Biosimilars Litigation